

## Healthcare Common Procedure Coding System Quarterly Update Effective January 1, 2023

The Centers for Medicare and Medicaid Services (CMS) publishes updates to the Healthcare Procedure Coding System (HCPCS) on a quarterly basis. Public use files may be downloaded from the "[HCPCS Quarterly Update](#)" page. Be sure to update any systems accordingly.

### Proprietary Lab Analyses (PLA)

0356U Oncology (oropharyngeal), evaluation of 17 dna biomarkers using droplet digital pcr (ddpcr), cell-free dna, algorithm reported as a prognostic risk score for cancer recurrence

0357U Oncology (melanoma), artificial intelligence (ai)-enabled quantitative mass spectrometry analysis of 142 unique pairs of glycopeptide and product fragments, plasma, prognostic, and predictive algorithm reported as likely, unlikely, or uncertain benefit from immunotherapy agents

0359U Oncology (prostate cancer), analysis of all prostate-specific antigen (PSA) structural isoforms by phase separation and immunoassay, plasma, algorithm reports risk of cancer

0360U Oncology (lung), enzyme-linked immunosorbent assay (ELISA) of 7 autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, MAGE A4, and HuD), plasma, algorithm reported as a categorical result for risk of malignancy

0362U - Oncology (papillary thyroid cancer), gene-expression profiling via targeted hybrid capture-enrichment rna sequencing of 82 content genes and 10 housekeeping genes, formalin-fixed paraffin embedded (ffpe) tissue, algorithm reported as one of three molecular subtypes

0363U Oncology (urothelial), mrna, gene expression profiling by real-time quantitative pcr of 5 genes (mdk, hoxa13, cdc2 [cdk1], igfbp5, and cxcr2), utilizing urine, algorithm incorporates age, sex, smoking history, and macrohematuria frequency, reported as a risk score for having urothelial carcinoma

### Drugs

#### NEW Codes

J0893 Injection, decitabine (sun pharma) not therapeutically equivalent to J0894, 1 mg

J1456 Injection, fosaprepitant (teva), not therapeutically equivalent to J1453, 1 mg

J1954 Injection, leuprolide acetate for depot suspension

J9046 Injection, bortezomib (dr. reddy's), not therapeutically equivalent to J9041, 0.1 mg

J9048 Injection, bortezomib (fesenius kabi) not therapeutically equivalent to J9041, 0.1 mg

J9049 Injection, bortezomib (hospira) not therapeutically equivalent to J9041, 0.1 mg

J9314 Injection, pemetrexed (teva) not therapeutically equivalent to J9305, 10 mg

J9393 Injection, fulvestrant (teva) not therapeutically equivalent to J9395, 25 mg

J9394 Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to J9395, 25 mg

Q2156 Bevacizumab-maly, biosimilar, (Alymsys), 10 mg

#### Discontinued codes

C9142 Injection, alymsys, 10 mg

J9044 Injection, bortezomib, not otherwise specified, 0.1 mg

#### Revised codes

J9041 Injection, bortezomib, 0.1 mg

### Modifiers

#### LU – Fractionated payment of cart-t therapy

Per Medicare instruction included in the [HCPCS Application summary](#), the physician office would bill multiple claims for fractional units for the same date of service and same procedure using the LU modifier. Medicare Administrative Contractors (MAC) will issue instructions for appropriate use and may also provide instructions on the use of modifier 76. The modifier is not intended for claims submission under OPPS or IPPS. Modifier is retroactively effective for dates of service on or after January 1, 2022. For additional reference, see [MLN article MM12928](#) regarding the updated NCD for CAR-T therapy.

Individual payer policies may vary on the use of the modifier, therefore refer to payer guidelines.